Biological Products, (No Diagnostic Substances)
Solid Biosciences Inc. (SLDB) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 38/100 — a percentile rank of Solid Biosciences Inc.’s fundamentals against Manufacturing peers.
Is Solid Biosciences Inc. overvalued? P/B looks fair vs its 5-year range.
Consensus: Buy from 23 analysts (Buy 18 · Hold 5).
Average price target: $22.25 (+245.5% vs $6.44); range $18–$26.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 9 · Open-market sells: 3 · Net: +$64.5M
Coordinated block · likely financing, not open-market conviction.
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!